Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome
JACC: Cardiovascular Interventions · 2024
DOI: 10.1016/j.jcin.2024.09.058 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Wijnand K den Dekker und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: w.dendekker@erasmusmc.nl. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Time-to-Treatment. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BIOTRONIK SE & Co KG.
Abstract (Originalsprache)
BACKGROUND: In patients with acute coronary syndromes (ACS) and multivessel coronary disease, immediate complete revascularization was noninferior to staged complete revascularization for the primary composite outcome at 1 year. The authors report clinical outcomes at 2 years of follow-up. METHODS: Patients with ACS and multivessel coronary disease were randomly assigned to immediate complete revascularization or to staged complete revascularization at 29 sites in Europe. The primary outcome was the composite of all-cause mortality, myocardial infarction, any unplanned ischemia-driven revascularization, and cerebrovascular event. RESULTS: In total, 764 patients were enrolled and randomly allocated to the immediate complete revascularization arm and 761 to the staged complete revascularization arm. Two-year follow-up was complete for 97.6% of patients. At 2 years, the primary outcome had occurred in 12.5% of patients in the immediate complete revascularization group and 12.4% of patients in the staged complete revascularization group (HR: 0.98; 95% CI: 0.73-1.30; P = 0.88). Myocardial infarction occurred more frequently in the staged complete revascularization group (6.2% vs 3.8%; HR: 0.60; 95% CI: 0.37-0.96; P = 0.032). In the immediate complete revascularization and staged complete revascularization groups, the rates of all-cause mortality (3.3% vs 2.0%; HR: 1.67; 95% CI: 0.88-3.16; P = 0.12), any unplanned ischemia-driven revascularization (7.0% vs 7.9%; HR: 0.87; 95% CI: 0.60-1.26; P = 0.57), and cerebrovascular event (2.5% vs 1.7%; HR: 1.39; 95% CI: 0.68-2.83; P = 0.37) were not significantly different. CONCLUSIONS: In patients with ACS and multivessel disease, there was no significant difference between immediate complete revascularization and staged complete revascularization with respect to the composite outcome of all-cause mortality, myocardial infarction, any unplanned ischemia-driven revascularization, and cerebrovascular event at 2 years. Immediate complete revascularization was associated with a significant reduction in myocardial infarction, mainly due to fewer early events. (Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease [BioVasc]; NCT03621501).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: w.dendekker@erasmusmc.nl.
- Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Cardiovascular Medicine, University Hospital Leuven, Leuven, Belgium.
- Department of Cardiology, Haga Hospital, the Hague, the Netherlands.
- Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
- Interventional Cardiology Department, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Förderung
- BIOTRONIK SE & Co KG
Zitieren
APA
den Dekker, W. K., Elscot, J. J., Bennett, J., Schotborgh, C. E., van der Schaaf, R., Sabaté, M., Moreno, R., Ameloot, K., van Bommel, R., Forlani, D., van Reet, B., Esposito, G., Dirksen, M. T., Ruifrok, W. P. T., Everaert, B. R. C., Van Mieghem, C., Cummins, P., Lenzen, M., Brugaletta, S., …, & BIOVASC Investigators (2024). Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.09.058
Vancouver
den Dekker WK, Elscot JJ, Bennett J, Schotborgh CE, van der Schaaf R, Sabaté M, et al. Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.09.058
BibTeX
@article{denDekker2024,
author = {den Dekker, Wijnand K and Elscot, Jacob J and Bennett, Johan and Schotborgh, Carl E and van der Schaaf, Rene and Sabaté, Manel and Moreno, Raúl and Ameloot, Koen and van Bommel, Rutger and Forlani, Daniele and van Reet, Bert and Esposito, Giovanni and Dirksen, Maurits T and Ruifrok, Willem P T and Everaert, Bert R C and Van Mieghem, Carlos and Cummins, Paul and Lenzen, Mattie and Brugaletta, Salvatore and Boersma, Eric and Van Mieghem, Nicolas M and Diletti, Roberto and BIOVASC Investigators, BIOVASC Investigators},
title = {Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome},
journal = {JACC: Cardiovascular Interventions},
year = {2024},
doi = {10.1016/j.jcin.2024.09.058}
}
EUVIMED